Costochondritis is the most common musculoskeletal cause of anterior chest wall pain. Here is where non-invasive PEMF fits — and the clinical protocol behind it.
July 2026 · 8 min read · Clinical Protocol
Chest pain can also arise from cardiac (heart attack, angina) or pulmonary (pulmonary embolism, pleurisy, pneumothorax) causes. Before chest pain is attributed to the chest wall, a physician must rule out these life-threatening causes. Costochondritis is a clinical diagnosis made by a doctor, usually after other causes are excluded. PEMF is applied only after a physician has diagnosed costochondritis.
Costochondritis is inflammation of the cartilage that connects the upper ribs to the breastbone (the costochondral junctions), most often at the second through fifth ribs. In most cases the cause is unknown (idiopathic), but it can appear after repetitive physical strain, heavy lifting, a prolonged cough following a respiratory infection, or local trauma. The pain arises from irritation and repeated strain of the cartilage and the surrounding soft tissue, sometimes with a local inflammatory and edema component. It is important to distinguish costochondritis — in which there is no visible swelling — from Tietze syndrome, which involves marked local swelling at the costochondral junction, usually at a single rib. Both are benign, but Tietze syndrome is rarer.
PEMF (Pulsed Electromagnetic Field) is a non-invasive treatment in which a pulsed magnetic field is delivered into the tissue. Mechanisms described in the literature include improved microcirculation, reduced edema, effects on inflammatory mediators, and reduced local nerve hypersensitivity. In costochondritis — a condition characterized by pain and irritation of cartilaginous and soft tissue — there is a clinical rationale for using PEMF together with relative rest and load reduction, aiming to support the reduction of pain and edema. PEMF does not replace medical diagnosis, and basic conservative care continues together with it. Its main advantage for the patient is that it is comfortable, with no injections and none of the systemic side effects of medication.
From the patient's perspective, the goal of PEMF is to ease pain and allow a fast, safe return to routine. PEMF is delivered while sitting or lying comfortably, requires no full undressing, and is completely painless. Because pain in costochondritis worsens with breathing and movement, reducing the pain allows deeper breathing and freer movement — breaking the pain–avoidance–stiffness cycle. Combining it with breathing guidance, gentle chest-wall stretching, and posture correction increases the benefit.
The costochondral junctions move with every breath. When the cartilage is irritated and inflamed, any expansion of the chest — a deep breath, a cough, or a laugh — stretches the sensitive tissue and triggers sharp pain. This is why many patients adopt shallow breathing, which can worsen stiffness.
The key distinguishing sign is tenderness on palpation: in costochondritis, pressing on the costochondral junction reproduces the pain, whereas cardiac pain is not worsened by palpation. However, this test does not replace medical evaluation — any chest pain requires a physician to rule out a cardiac cause before any treatment.
It must be stated up front: there is currently no dedicated controlled clinical trial of PEMF in costochondritis itself. The clinical rationale rests on general evidence for PEMF in joint and soft-tissue pain and on the mechanisms of action. In the 2025 multicenter RCT (n=91, 5 orthopedic clinics, PMC11914662), the PEMF group showed a 36% pain reduction versus 10% with standard care (p<0.0001), alongside roughly a 55% reduction in pain-medication use. That trial examined joint and soft-tissue pain in general — not costochondritis specifically — so it is extrapolated to the general tissue efficacy of the treatment. In addition, a review published in the Aesthetic Surgery Journal (Strauch et al., 2009, Albert Einstein College of Medicine, PubMed 19371845) describes PEMF easing soft-tissue pain and edema and promoting angiogenesis. Because costochondritis is characterized by tissue irritation and local edema, using PEMF is a reasonable clinical rationale — even though direct evidence for this specific condition is still limited.
PEMF does not replace the diagnosis or exclusion of cardiac/pulmonary causes of chest pain. PEMF systems are FDA cleared (510k) for pain and edema indications; use in costochondritis is derived from general soft-tissue efficacy and managed by clinical judgment.
Especially suitable for: patients with persistent or recurrent costochondritis that does not resolve with rest alone; patients who prefer a non-invasive option with no injections and no prolonged medication; patients sensitive to painkillers or with contraindications to anti-inflammatory drugs; and athletes seeking a controlled return to activity.
Contraindications — PEMF should not be used in:
| Parameter | PEMF | NSAIDs | Local Steroid Injection |
|---|---|---|---|
| Invasiveness | Non-invasive | Non-invasive (oral) | Invasive (injection) |
| Patient experience during treatment | Comfortable, painless | May cause GI side effects | May cause transient local pain |
| Systemic side effects | None | Possible (GI, kidney, blood pressure) | Mainly local |
| Practitioner work time | 0 minutes (Hands-Free) | — | ~15 minutes |
| FDA cleared | Not for the devices we supply — no FDA 510(k) or PMA. Other PEMF devices hold 510(k) for pain/edema; clearance is granted per model, not to the technology. Our Magnetobox unit carries CE. | Yes | Yes |
NSAIDs and rest remain an accepted first line, and PEMF works together with them as a calming, non-invasive treatment to reduce pain and edema.
No. Costochondritis usually resolves on its own, and PEMF may support the reduction of pain and edema, together with conservative care. It is not a miracle cure.
No. PEMF is entirely comfortable, with no injections and no pain. The patient sits or lies comfortably for about 30 minutes.
A minimum of 3 sessions is recommended to assess response. The series length is set by the practitioner's judgment and the patient's response, and initial improvement is usually felt after several sessions.
Yes. PEMF leads the clinic treatment, and physiotherapy, stretching, breathing guidance and any anti-inflammatory medication your doctor prescribed continue together with it.
Yes, especially if the load factors persist (prolonged coughing, repetitive strain, poor posture). Reducing loads and practicing breathing help lower the risk of recurrence.
Absolutely not. Any chest pain first requires medical evaluation to rule out a cardiac or pulmonary cause. PEMF is provided only after a physician has diagnosed costochondritis.
Seek urgent medical care if chest pain is accompanied by any of the following:
Over 70+ Israeli clinics serving a population of 9M — now expanding to the Philippines — have integrated PEMF into their treatment mix, offering patients a non-invasive, comfortable, drug-free option to ease chest wall pain and other tissue-pain conditions.
Request the full investment brief — machine specs, financials, and site selection for the Philippines market.
Request Investment Brief →